# Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

> **NCT02991898** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 3 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Burkitt Lymphoma
- Natural Killer Cell Malignancies
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndromes
- Large-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone B-Cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Prolymphocytic Leukemia
- Hodgkin Lymphoma
- Multiple Myeloma
- Acute Myelogenous Leukemia
- Biphenotypic Leukemia
- Undifferentiated Leukemia

## Interventions

- **BIOLOGICAL:** Infusion of Treg

## Key facts

- **NCT ID:** NCT02991898
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-16
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-06-20
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Considering new technology for product.
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991898, "Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02991898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*